Monitor blood glucose if applicable: Individuals with type 2 diabetes who are also taking insulin or sulfonylureas should monitor their blood glucose levels as directed by their clinical team, as dose adjustments to concurrent therapies may be necessary to reduce hypoglycaemia risk
Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford GM, Leibach FH
Abstract Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction
Compounded injectables pose greater risk "Compounding pharmacies are useful for many patients in need of hard-to-find medications or patient-specific formulations," said David Margraf, PharmD, PhD, pharmaceutical research scientist at the Resilient Drug Supply Project (RDSP)
Beyond skin-related effects, GHK-Cu is being studied for its anti-inflammatory and antioxidant activity, helping reduce oxidative stress and support healthier cellular function
